{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:11:24Z","timestamp":1740107484911,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00535-020-01721-8","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T20:02:46Z","timestamp":1598472166000},"page":"1150-1161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Durable response without recurrence to Tolvaptan improves long-term survival"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-1353","authenticated-orcid":false,"given":"Masato","family":"Nakai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Tokuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kitagataya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Shigesawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuharu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kawagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machiko","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Sho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"1721_CR1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2006.08.007","volume":"4","author":"R Planas","year":"2006","unstructured":"Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385\u201394.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1721_CR2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0016-5085(87)91007-9","volume":"93","author":"P Gines","year":"1987","unstructured":"Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites results of a randomized study. Gastroenterology. 1987;93:234\u201341.","journal-title":"Gastroenterology"},{"key":"1721_CR3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/gutjnl-2011-301255","volume":"62","author":"CD Tsien","year":"2013","unstructured":"Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62:131\u20137.","journal-title":"Gut"},{"key":"1721_CR4","doi-asserted-by":"crossref","first-page":"46369","DOI":"10.1038\/srep46369","volume":"7","author":"S Mandai","year":"2017","unstructured":"Mandai S, Furukawa S, Kodaka M, et al. Loop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy. Sci Rep. 2017;7:46369.","journal-title":"Sci Rep"},{"key":"1721_CR5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/hepr.13244","volume":"49","author":"T Hanai","year":"2019","unstructured":"Hanai T, Shiraki M, Miwa T, et al. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis. Hepatol Res. 2019;49:82\u201395.","journal-title":"Hepatol Res"},{"issue":"166\u201373","key":"1721_CR6","first-page":"73.e1","volume":"10","author":"AJ Montano-Loza","year":"2012","unstructured":"Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(166\u201373):73.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1721_CR7","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u2013112.","journal-title":"N Engl J Med"},{"key":"1721_CR8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hepr.12098","volume":"44","author":"I Sakaida","year":"2014","unstructured":"Sakaida I, Kawazoe S, Kajimura K, et al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:73\u201382.","journal-title":"Hepatol Res"},{"key":"1721_CR9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/hepr.12852","volume":"47","author":"I Sakaida","year":"2017","unstructured":"Sakaida I, Terai S, Kurosaki M, et al. Effectiveness and safety of Tolvaptan in liver cirrhosis patients with edema: interim results of post-marketing surveillance of Tolvaptan in liver cirrhosis (START study). Hepatol Res. 2017;47:1137\u201346.","journal-title":"Hepatol Res"},{"key":"1721_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-020-01691-x","author":"I Sakaida","year":"2020","unstructured":"Sakaida I, Terai S, Kurosaki M, et al. Real-world effectiveness and safety of Tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study). J Gastroenterol. 2020. https:\/\/doi.org\/10.1007\/s00535-020-01691-x.","journal-title":"J Gastroenterol"},{"key":"1721_CR11","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.4254\/wjh.v7.i12.1685","volume":"7","author":"T Ohki","year":"2015","unstructured":"Ohki T, Sato K, Yamada T, et al. Efficacy of Tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol. 2015;7:1685\u201393.","journal-title":"World J Hepatol"},{"key":"1721_CR12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1159\/000448828","volume":"34","author":"H Chishina","year":"2016","unstructured":"Chishina H, Hagiwara S, Nishida N, et al. Clinical factors predicting the effect of Tolvaptan for refractory ascites in patients with decompensated liver cirrhosis. Dig Dis. 2016;34:659\u201364.","journal-title":"Dig Dis"},{"key":"1721_CR13","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2169\/internalmedicine.55.6819","volume":"55","author":"T Iwamoto","year":"2016","unstructured":"Iwamoto T, Maeda M, Hisanaga T, et al. Predictors of the effect of Tolvaptan on the prognosis of cirrhosis. Intern Med. 2016;55:2911\u20136.","journal-title":"Intern Med"},{"key":"1721_CR14","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.3748\/wjg.v22.i21.5104","volume":"22","author":"A Nakagawa","year":"2016","unstructured":"Nakagawa A, Atsukawa M, Tsubota A, et al. Usefulness of portal vein pressure for predicting the effects of Tolvaptan in cirrhotic patients. World J Gastroenterol. 2016;22:5104\u201313.","journal-title":"World J Gastroenterol"},{"key":"1721_CR15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40261-016-0434-7","volume":"36","author":"T Yamada","year":"2016","unstructured":"Yamada T, Ohki T, Hayata Y, et al. Potential effectiveness of Tolvaptan to improve ascites unresponsive to standard diuretics and overall survival in patients with decompensated liver cirrhosis. Clin Drug Investig. 2016;36:829\u201335.","journal-title":"Clin Drug Investig"},{"key":"1721_CR16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/hepr.12778","volume":"47","author":"Y Hiramine","year":"2017","unstructured":"Hiramine Y, Uto H, Imamura Y, et al. Efficacy of vasopressin V2 receptor antagonist Tolvaptan in treatment of hepatic edema. Hepatol Res. 2017;47:542\u201357.","journal-title":"Hepatol Res"},{"key":"1721_CR17","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hepr.12826","volume":"47","author":"H Kawaratani","year":"2017","unstructured":"Kawaratani H, Fukui H, Moriya K, et al. Predictive parameter of Tolvaptan effectiveness in cirrhotic ascites. Hepatol Res. 2017;47:854\u201361.","journal-title":"Hepatol Res"},{"key":"1721_CR18","doi-asserted-by":"crossref","first-page":"e0174649","DOI":"10.1371\/journal.pone.0174649","volume":"12","author":"Y Komiyama","year":"2017","unstructured":"Komiyama Y, Kurosaki M, Nakanishi H, et al. Prediction of diuretic response to Tolvaptan by a simple, readily available spot urine Na\/K ratio. PLoS ONE. 2017;12:e0174649.","journal-title":"PLoS ONE"},{"key":"1721_CR19","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1111\/hepr.12716","volume":"47","author":"H Uojima","year":"2017","unstructured":"Uojima H, Kinbara T, Hidaka H, et al. Close correlation between urinary sodium excretion and response to Tolvaptan in liver cirrhosis patients with ascites. Hepatol Res. 2017;47:E14\u2013e21.","journal-title":"Hepatol Res"},{"key":"1721_CR20","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/jgh.14047","volume":"33","author":"M Atsukawa","year":"2018","unstructured":"Atsukawa M, Tsubota A, Kato K, et al. Analysis of factors predicting the response to Tolvaptan in patients with liver cirrhosis and hepatic edema. J Gastroenterol Hepatol. 2018;33:1256\u201363.","journal-title":"J Gastroenterol Hepatol"},{"key":"1721_CR21","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2169\/internalmedicine.0629-17","volume":"57","author":"M Hayashi","year":"2018","unstructured":"Hayashi M, Abe K, Fujita M, et al. Association between the serum sodium levels and the response to Tolvaptan in liver cirrhosis patients with ascites and hyponatremia. Intern Med. 2018;57:2451\u20138.","journal-title":"Intern Med"},{"key":"1721_CR22","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1111\/hepr.12988","volume":"48","author":"M Nakai","year":"2018","unstructured":"Nakai M, Ogawa K, Takeda R, et al. Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of Tolvaptan in patients with liver cirrhosis. Hepatol Res. 2018;48:E311\u2013E319319.","journal-title":"Hepatol Res"},{"key":"1721_CR23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40261-018-0714-5","volume":"39","author":"Y Arase","year":"2019","unstructured":"Arase Y, Kagawa T, Tsuruya K, et al. impaired renal function may not negate the efficacy of Tolvaptan in the treatment of cirrhotic patients with refractory ascites. Clin Drug Investig. 2019;39:45\u2013544.","journal-title":"Clin Drug Investig"},{"key":"1721_CR24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000494438","volume":"37","author":"Y Kida","year":"2019","unstructured":"Kida Y. Positive response to Tolvaptan treatment would be a good prognostic factor for cirrhotic patients with ascites. Dig Dis. 2019;37:239\u201346.","journal-title":"Dig Dis"},{"key":"1721_CR25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jphs.2019.01.015","volume":"139","author":"E Sagawa","year":"2019","unstructured":"Sagawa E, Okubo H, Ando H, et al. Plasma concentration and efficacy of Tolvaptan in cirrhotic patients with refractory ascites. J Pharmacol Sci. 2019;139:373\u20136.","journal-title":"J Pharmacol Sci"},{"key":"1721_CR26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00535-017-1366-6","volume":"53","author":"Y Hiramine","year":"2018","unstructured":"Hiramine Y, Uojima H, Nakanishi H, et al. Response criteria of Tolvaptan for the treatment of hepatic edema. J Gastroenterol. 2018;53:258\u201368.","journal-title":"J Gastroenterol"},{"key":"1721_CR27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/jgh.14784","volume":"35","author":"I Bellos","year":"2020","unstructured":"Bellos I, Kontzoglou K, Perrea DN. Predictors of Tolvaptan short-term response in patients with refractory ascites: a meta-analysis. J Gastroenterol Hepatol. 2020;35:182\u201391.","journal-title":"J Gastroenterol Hepatol"},{"key":"1721_CR28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406\u201360.","journal-title":"J Hepatol"},{"key":"1721_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14965","author":"M Atsukawa","year":"2019","unstructured":"Atsukawa M, Tsubota A, Takaguchi K, et al. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with Tolvaptan for hepatic edema. J Gastroenterol Hepatol. 2019. https:\/\/doi.org\/10.1111\/jgh.14965.","journal-title":"J Gastroenterol Hepatol"},{"key":"1721_CR30","first-page":"142","volume":"32","author":"A Rimola","year":"2000","unstructured":"Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Int Ascites Club J Hepatol. 2000;32:142\u201353.","journal-title":"Int Ascites Club J Hepatol"},{"key":"1721_CR31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","volume":"62","author":"P Angeli","year":"2015","unstructured":"Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968\u201374.","journal-title":"J Hepatol"},{"key":"1721_CR32","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1721_CR33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693\u20139.","journal-title":"N Engl J Med"},{"key":"1721_CR34","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/he.2000.5852","volume":"31","author":"M Malinchoc","year":"2000","unstructured":"Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864\u201371.","journal-title":"Hepatology"},{"key":"1721_CR35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hep.21563","volume":"45","author":"PS Kamath","year":"2007","unstructured":"Kamath PS, Kim WR, Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797\u2013805.","journal-title":"Hepatology"},{"key":"1721_CR36","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179\u2013c184184.","journal-title":"Nephron Clin Pract"},{"key":"1721_CR37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/bj2880285","volume":"288","author":"RG Maatman","year":"1992","unstructured":"Maatman RG, van de Westerlo EM, van Kuppevelt TH, et al. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J. 1992;288:285\u201390.","journal-title":"Biochem J"},{"key":"1721_CR38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11010-005-9047-9","volume":"284","author":"A Kamijo","year":"2006","unstructured":"Kamijo A, Sugaya T, Hikawa A, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006;284:175\u201382.","journal-title":"Mol Cell Biochem"},{"key":"1721_CR39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.ki.5002721","volume":"73","author":"D Portilla","year":"2008","unstructured":"Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008;73:465\u201372.","journal-title":"Kidney Int"},{"key":"1721_CR40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/j.ajkd.2005.11.006","volume":"47","author":"T Nakamura","year":"2006","unstructured":"Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 2006;47:439\u201344.","journal-title":"Am J Kidney Dis"},{"key":"1721_CR41","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2215\/CJN.09430913","volume":"9","author":"JM Belcher","year":"2014","unstructured":"Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol. 2014;9:1857\u201367.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1721_CR42","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.26980","volume":"60","author":"JM Belcher","year":"2014","unstructured":"Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60:622\u201332.","journal-title":"Hepatology"},{"key":"1721_CR43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/hepr.13337","volume":"49","author":"Y Hiramine","year":"2019","unstructured":"Hiramine Y, Uto H, Mawatari S, et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites. Hepatol Res. 2019;49:765\u201377.","journal-title":"Hepatol Res"},{"key":"1721_CR44","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/jgh.14524","volume":"34","author":"T Iwamoto","year":"2019","unstructured":"Iwamoto T, Maeda M, Saeki I, et al. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites. J Gastroenterol Hepatol. 2019;34:1231\u20135.","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-020-01721-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-020-01721-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-020-01721-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T04:06:20Z","timestamp":1668053180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-020-01721-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s00535-020-01721-8","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"5 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Professor Naoya Sakamoto received lecture fees from Bristol Myers Squibb and Pharmaceutical K.K, grants and endowments from MSD K. K and Chugai Pharmaceutical Co., Ltd, and a research grant from Gilead Sciences Inc. Dr. Goki Suda received research grants from Bristol Myers Squibb. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}